Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NewAmsterdam Pharma Company ( (NAMS) ) just unveiled an update.
On September 2, 2025, NewAmsterdam Pharma Company released an updated corporate investor presentation highlighting significant progress in its clinical trials for obicetrapib, a promising treatment for lowering LDL-C levels. The presentation detailed the company’s strategic plans, including securing funding for a potential U.S. commercial launch and expanding its workforce. The company’s trials have shown favorable results, indicating a substantial market opportunity, particularly in the U.S., where many patients are not meeting cholesterol goals with existing treatments.
The most recent analyst rating on (NAMS) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
The overall score reflects strong technical momentum and positive corporate events, which are offset by financial performance challenges and valuation concerns. The company’s strategic advances in drug development and regulatory milestones are significant positives, but profitability and valuation remain key risks.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. operates in the pharmaceutical industry, focusing on the development of therapies for cardiometabolic diseases. The company is working on obicetrapib, a CETP inhibitor aimed at lowering LDL-C levels, with potential applications for patients not achieving cholesterol goals with current treatments.
Average Trading Volume: 896,643
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.71B
For an in-depth examination of NAMS stock, go to TipRanks’ Overview page.